Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome

Journal of the Neurological Sciences

Volumn 349, Issue 1-2, 2015, Pages 77-83

  Sun, Xuhong ^a   Berthiller, Julien ^b,c   Derex, Laurent ^c   Trouillas, Paul ^c   Diallo, Laho ^c   Hanss, Michel ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Alpha2 antiplasmin; Factor XIII; Fibrin; Fibrinogen; Plasminogen; Thrombolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOLYTIC AGENT; FIBRINOLYTIC FACTOR; PLASMINOGEN; ANTIFIBRINOLYTIC AGENT; FIBRIN; FIBRIN FRAGMENT D; FORMYCIN DERIVATIVE; FORMYCIN DIPHOSPHATE; RIBONUCLEOTIDE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CLINICAL ASSESSMENT; DIASTOLIC BLOOD PRESSURE; FIBRINOLYTIC THERAPY; HEMATOCRIT; HEMOSTASIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; BLOOD; CEREBRAL INFARCTION; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-2-ANTIPLASMIN; ANTIFIBRINOLYTIC AGENTS; CEREBRAL INFARCTION; FACTOR XIII; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYTIC AGENTS; FORMYCINS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN; RIBONUCLEOTIDES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84923950417     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.12.029     Document Type: Article

References (28)

1. The National Institute of Neurological Disorders Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
2. W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Davalos, and D. Guidetti Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
3. M. Rubiera, J. Alvarez-Sabín, M. Ribo, J. Montaner, E. Santamarina, and J.F. Arenillas Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke Stroke 36 2005 1452 1456
4. A.V. Alexandrov, and J.C. Grotta Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator Neurology 59 2002 862 867
5. M. Ribo, J. Alvarez-Sabín, J. Montaner, F. Romero, P. Delgado, and M. Rubiero Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques Stroke 37 2006 1000 1004
6. M. Fisher, and R. Francis Altered coagulation in cerebral ischemia: platelet, thrombin, and plasmin activity Arch Neurol 47 1990 1075 1079
7. K. Takano, T. Yamaguchi, and K. Uchida Markers of a hypercoagulable state following acute ischemic stroke Stroke 23 1992 194 198
8. H.J. Koch, M. Horn, U. Bogdahn, and G.W. Ickenstein The relationship between plasma D-dimer concentrations and acute ischemic stroke subtypes J Stroke Cerebrovasc Dis 14 2005 75 79
9. T. Tombul, C. Atbas, and O. Anlar Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction J Clin Neurosci 12 2005 429 434
10. T. Dahl, F. Kontny, and C.E. Slagsvold Lipoprotein(a), other lipoproteins and hemostatic profiles in patients with ischemic stroke: the relation to cardiogenic embolism Cerebrovasc Dis 10 2000 110 117
11. W. Ageno, S. Finazzi, L. Steidl, M.G. Biotti, V. Mera, and G. Melzi D'Eril Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes Arch Intern Med 162 2002 2589 2593
12. J. Montaner, M. Perea-Gainza, P. Delgado, M. Ribo, P. Chacon, and A. Rosell Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers Stroke 39 2008 2280 2287
13. F.J. Alvarez-Perez, M. Castelo-Branco, and J. Alvarez-Sabin Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke J Neurol Neurosurg Psychiatry 82 2011 986 992
14. I. Gosk-Bierska, R.D. McBane, Y. Wu, J. Mruk, A. Tafur, and T. McLeod Platelet factor XIII gene expression and embolic propensity in atrial fibrillation Thromb Haemost 106 2011 75 82
15. M. Ribo, J. Montaner, C.A. Molina, J.F. Arenillas, E. Santamarina, and M. Quintana Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator Stroke 35 2004 2123 2127
16. J. Isenegger, N. Meier, B. Lämmle, L. Alberio, U. Fischer, and K. Nedeltchev D-dimers predict stroke subtype when assessed early Cerebrovasc Dis 29 2010 82 86
17. J. Marti-Fabregas, M. Borrell, D. Cocho, R. Belvis, M. Castellanos, and J. Montaner Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA Neurology 65 2005 366 370
18. D. Tanne, R.F. Macko, Y. Lin, B.C. Tilley, S.R. Levine, and NINDS rtPA Stroke Study Group Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke Stroke 37 2006 1798 1804
19. K. Fassbender, C.E. Dempfle, O. Mielke, A. Schwartz, M. Daffertshofer, and Ch. Eschenfelder Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator Stroke 30 1999 2101 2104
20. P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, and M. Hanss Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis Stroke 35 2004 1323 1328
21. P. Trouillas, N. Nighoghossian, J.C. Getenet, G. Riche, P. Neuschwander, and J.C. Froment Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke Stroke 27 1996 882 890
22. N.J. Mutch, L. Thomas, N.R. Moore, K.M. Lisiak, and N.A. Booth TAFIa, PAI-1 and α2-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots J Thromb Haemost 5 2007 812 817
23. M.W. Mosesson, K.R. Siebenlist, I. Hernandez, K.N. Lee, V.J. Christiansen, and P.A. McKee Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation J Thromb Haemost 6 2008 1565 1570
24. K.R. Siebenlist, D.A. Meh, and M.W. Mosesson Plasma factor XIII binds specifically to fibrinogen molecules containing γ chains Biochemistry 35 1996 10448 10453
25. L. Muszbek, Z. Bereczky, Z. Bagoly, I. Komáromi, and É. Katona Factor XIII: a coagulation factor with multiple plasmatic and cellular functions Physiol Rev 91 2011 931 972
26. D.M. Rider, and J. McDonagh Resistance of factor XIII to degradation or activation by plasmin Biochim Biophys Acta 675 1981 171 177
27. F. Stehling, R. Weber, A. Ozcelik, M. Bröcker, L. Volbracht, and H.C. Diener Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic threrapytherapy Neurosci Lett 441 2008 39 43
28. M. Mirshahi, J. Soria, C. Soria, J.Y. Perrot, and C. Boucheix A latex immunoassay of fibrin/fibrinogen degradation products in plasma using a monoclonal antibody Thromb Res 44 1986 715 728